Your browser doesn't support javascript.
loading
Four groups of type 2 diabetes contribute to the etiological and clinical heterogeneity in newly diagnosed individuals: An IMI DIRECT study.
Wesolowska-Andersen, Agata; Brorsson, Caroline A; Bizzotto, Roberto; Mari, Andrea; Tura, Andrea; Koivula, Robert; Mahajan, Anubha; Vinuela, Ana; Tajes, Juan Fernandez; Sharma, Sapna; Haid, Mark; Prehn, Cornelia; Artati, Anna; Hong, Mun-Gwan; Musholt, Petra B; Kurbasic, Azra; De Masi, Federico; Tsirigos, Kostas; Pedersen, Helle Krogh; Gudmundsdottir, Valborg; Thomas, Cecilia Engel; Banasik, Karina; Jennison, Chrisopher; Jones, Angus; Kennedy, Gwen; Bell, Jimmy; Thomas, Louise; Frost, Gary; Thomsen, Henrik; Allin, Kristine; Hansen, Tue Haldor; Vestergaard, Henrik; Hansen, Torben; Rutters, Femke; Elders, Petra; t'Hart, Leen; Bonnefond, Amelie; Canouil, Mickaël; Brage, Soren; Kokkola, Tarja; Heggie, Alison; McEvoy, Donna; Hattersley, Andrew; McDonald, Timothy; Teare, Harriet; Ridderstrale, Martin; Walker, Mark; Forgie, Ian; Giordano, Giuseppe N; Froguel, Philippe.
Afiliação
  • Wesolowska-Andersen A; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Brorsson CA; Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark.
  • Bizzotto R; Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Mari A; C.N.R. Institute of Neuroscience, Padova, Italy.
  • Tura A; C.N.R. Institute of Neuroscience, Padova, Italy.
  • Koivula R; C.N.R. Institute of Neuroscience, Padova, Italy.
  • Mahajan A; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Vinuela A; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Tajes JF; Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland.
  • Sharma S; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Haid M; Research Unit Molecular Endocrinology And Metabolism, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health (GmbH), Neuherberg, Germany.
  • Prehn C; Research Unit Molecular Endocrinology And Metabolism, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health (GmbH), Neuherberg, Germany.
  • Artati A; Research Unit Molecular Endocrinology And Metabolism, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health (GmbH), Neuherberg, Germany.
  • Hong MG; Research Unit Molecular Endocrinology And Metabolism, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health (GmbH), Neuherberg, Germany.
  • Musholt PB; Affinity Proteomics, Science for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Solna, Sweden.
  • Kurbasic A; R&D Global Development, Translational Medicine & Clinical Pharmacology (TMCP), Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.
  • De Masi F; University of Lund, Clinical Sciences, Malmö, Sweden.
  • Tsirigos K; Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark.
  • Pedersen HK; Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark.
  • Gudmundsdottir V; Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark.
  • Thomas CE; Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark.
  • Banasik K; Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark.
  • Jennison C; Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Jones A; Department of Mathematical Sciences, University of Bath, Bath, UK.
  • Kennedy G; University of Exeter Medical School, Exeter, UK.
  • Bell J; The Immunoassay Biomarker Core Laboratory, Shool of Medicine, University of Dundee, Dundee, UK.
  • Thomas L; Research Centre for Optimal Health, Deparment of Life Sciences, University of Westminster, London, UK.
  • Frost G; Research Centre for Optimal Health, Deparment of Life Sciences, University of Westminster, London, UK.
  • Thomsen H; Section for Nutrition Research, Faculty of Medicine, Hammersmith Campus, Imperial College London, London, UK.
  • Allin K; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Hansen TH; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Vestergaard H; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Hansen T; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Rutters F; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Elders P; Department of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, Amsterdam UMC-location VUmc, Amsterdam, the Netherlands.
  • t'Hart L; Department of General Practice, Amsterdam UMC-location VUmc, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands.
  • Bonnefond A; Department of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, Amsterdam UMC-location VUmc, Amsterdam, the Netherlands.
  • Canouil M; Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands.
  • Brage S; INSERM UMR 1283, CNRS UMR 8199, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille, University of Lille, Lille University Hospital, Lille, France.
  • Kokkola T; INSERM UMR 1283, CNRS UMR 8199, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille, University of Lille, Lille University Hospital, Lille, France.
  • Heggie A; MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, UK.
  • McEvoy D; Department of Medicine, University of Eastern Finland, Kuopio, Finland.
  • Hattersley A; Institute of Cellular Medicine, Newcastle University, Newcastle, UK.
  • McDonald T; Diabetes Research Network, Royal Victoria Infirmary, Newcastle, UK.
  • Teare H; University of Exeter Medical School, Exeter, UK.
  • Ridderstrale M; University of Exeter Medical School, Exeter, UK.
  • Walker M; Centre for Health, Law and Emerging Technologies (HeLEX), Faculty of Law, University of Oxford, Oxford, UK.
  • Forgie I; University of Lund, Clinical Sciences, Malmö, Sweden.
  • Giordano GN; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, UK.
  • Froguel P; University of Dundee, Dundee, UK.
Cell Rep Med ; 3(1): 100477, 2022 01 18.
Article em En | MEDLINE | ID: mdl-35106505
ABSTRACT
The presentation and underlying pathophysiology of type 2 diabetes (T2D) is complex and heterogeneous. Recent studies attempted to stratify T2D into distinct subgroups using data-driven approaches, but their clinical utility may be limited if categorical representations of complex phenotypes are suboptimal. We apply a soft-clustering (archetype) method to characterize newly diagnosed T2D based on 32 clinical variables. We assign quantitative clustering scores for individuals and investigate the associations with glycemic deterioration, genetic risk scores, circulating omics biomarkers, and phenotypic stability over 36 months. Four archetype profiles represent dysfunction patterns across combinations of T2D etiological processes and correlate with multiple circulating biomarkers. One archetype associated with obesity, insulin resistance, dyslipidemia, and impaired ß cell glucose sensitivity corresponds with the fastest disease progression and highest demand for anti-diabetic treatment. We demonstrate that clinical heterogeneity in T2D can be mapped to heterogeneity in individual etiological processes, providing a potential route to personalized treatments.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Cell Rep Med Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Cell Rep Med Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido